Stiripentol for focal refractory epilepsy

Brigo, Francesco; Storti, Monica; Igwe, Stanley C.

doi:10.1002/14651858.cd009887.pub3

Cited by 9 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the efficacy of stiripentol as addon treatment for patients with focal refractory epilepsy, as well as for the treatment of super-refractory status epilepticus have also been evaluated in clinical trials (78,79).…”

Section: Stiripentolmentioning

confidence: 99%

Advances and Limitations in Pharmacotherapy of Epilepsy

Rapacz¹

2018

Acta Poloniae Pharmaceutica - Drug Research

View full text Add to dashboard Cite

Epilepsy is a chronic neurologic disorder that affects about 0.7% of the population. Patients with epilepsy suffer from recurrent seizures, which can be focal or generalized in nature. The third-generation of anticonvulsant drugs includes lacosamide, rufinamide, vigabatrin, retigabine, perampanel, eslicarbazepine acetate, brivaracetam, and stiripentol. Other compounds, such as ganaxolone, cannabidiol, selurampanel, and everolimus among others, with different mechanisms of action are currently in clinical development. Furthermore, numerous compounds or classes of compounds are investigated in preclinical studies. Nevertheless, about 30% of epilepsy patients suffer from uncontrolled seizures despite pharmacotherapy, including the third-generation of anticonvulsant drugs. Additionally, the occurrence of adverse drug effects is responsible for poor compliance as well as discontinuation of the therapy, in up to 25% of patients before having reached the effective dose amount. Neuropsychiatric undesirable effects include depression, aggression, irritable mood, anxiety, mood instability, paranoid ideation, delusions, hallucinations. Moreover, suicidal ideation and behavior have been reported in patients treated with anticonvulsant drugs.

show abstract

Section: Stiripentolmentioning

confidence: 99%

Advances and Limitations in Pharmacotherapy of Epilepsy

Rapacz¹

2018

Acta Poloniae Pharmaceutica - Drug Research

View full text Add to dashboard Cite

show abstract

“…They screened 20 antiepileptic compounds on the purified mammalian enzyme and found that stiripentol (a new generation drug [30]) is endowed with inhibition activity on both LDH-A and -B, at the concentration of 500 M. Inhibition activity appeared slightly increased with a derivative of this molecule, which lacks the hydroxyl group and tertiary-butyl group of stiripentol (isosafrole, at 500 M) (Fig.…”

Section: Epilepsy As a Disease Of Energy Metabolismmentioning

confidence: 99%

Lactate Dehydrogenase Inhibition: Exploring Possible Applications Beyond Cancer Treatment

et al. 2016

View full text Add to dashboard Cite

Lactate dehydrogenase (LDH) inhibition is considered a worthwhile attempt in the development of innovative anticancer strategies. Unfortunately, in spite of the involvement of several research institutions and pharma-companies, the discovery of LDH inhibitors with drug-like properties seems a hardly resolvable challenge. While awaiting new advancements, in the present review we will examine other pathologic conditions characterized by increased glycolysis and LDH activity, which could potentially benefit from LDH inhibition. The rationale for targeting LDH activity in these contexts is the same justifying the LDH-based approach in anticancer therapy: because of the enzyme position at the end of glycolytic pathway, LDH inhibitors are not expected to hinder glucose metabolism of normal cells. Moreover, we will summarize the latest contributions in the discovery of enzyme inhibitors and try to glance over the reasons underlying the complexity of this research.

show abstract

“…Other reviews presented findings only on a specific syndrome (such as Dravet Syndrome or Lennox-Gastaut Syndrome), 10,11 the efficacy of specific treatments, 12,13 or specific outcomes (such as literacy and language). 14,15 We aimed to capture a comprehensive understanding of focal seizures by examining a wide range of outcomes, including incidence and prevalence, humanistic outcomes (mortality, morbidity, quality of life), and economic outcomes (health care utilization, health care costs).…”

mentioning

confidence: 99%

The Humanistic and Economic Burden of Pediatric Focal Seizures in the United States

et al. 2020

View full text Add to dashboard Cite

Objective: To better understand the humanistic and economic burden of focal seizures in children 2-12 years old. Methods: We conducted a targeted literature review by searching MEDLINE for English-language publications reporting on children 2-12 years old with focal seizures published in the United States since 2008. Results: Thirty-five publications were included. Incidence of focal seizures was 23.2 to 47.1 per 100,000 children per year; prevalence was 2.0 per 1,000 children, and ranged from 1.6 - 2.6 per 1,000 in patients of any age. Life expectancy was 47.3-61.8 years among children 3-12 years old. Patients took several antiepileptic drugs and experienced frequent seizures, sleep disorders, mood disorders, migraine, and seizure-related injuries (eg, bone fractures, sprains, open wounds). Children with focal seizures scored below average on cognitive assessments and up to 42%, 16%, and 19% had depression, anxiety, and attention-deficit disorder, respectively. Patients of any age had about 10 outpatient visits (2 epilepsy-related), 2 inpatient visits (less than 1 epilepsy-related), and 24 procedures (1 epilepsy-related) per year. Medication adherence was low: only half of pediatric patients maintained ≥90% adherence over 6 months. Annual total health care costs among patients of any age ranged from $18,369 - 38,549; first-year total health care costs for children were $19,883. Conclusions: Incidence and prevalence of focal seizures is high and the humanistic and economic burdens are significant. Future studies focused exclusively on children with focal seizures are needed to more precisely describe the burden. We also suggest further research and implementation of methods to improve medication adherence as an approach to lessen burden on these young patients.

show abstract

Stiripentol for focal refractory epilepsy

Cited by 9 publications

References 17 publications

Advances and Limitations in Pharmacotherapy of Epilepsy

Advances and Limitations in Pharmacotherapy of Epilepsy

Lactate Dehydrogenase Inhibition: Exploring Possible Applications Beyond Cancer Treatment

The Humanistic and Economic Burden of Pediatric Focal Seizures in the United States

Contact Info

Product

Resources

About